Navigation Links
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements
Date:7/21/2014

oking statements include, but are not limited to, statements regarding Valeant's offer to acquire Allergan, its financing of the proposed transaction, its expected future performance (including expected results of operations and financial guidance), and the combined company's future financial condition, operating results, strategy and plans.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," "opportunity," "tentative," "positioning," "designed," "create," "predict," "project," "seek," "ongoing," "upside," "increases" or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to numerous assumptions, risks and uncertainties that change over time and could cause actual results to differ materially from those described in the forward-looking statements.  These assumptions, risks and uncertainties include, but are not limited to, assumptions, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the SEC and the Canadian Securities Administrators (the "CSA") and assumptions, risks and uncertainties relating to the proposed merger, as detailed from time to time in Valeant's filings with the SEC and the CSA, which factors are incorporated herein by reference.  Important factors that could cause actual results to differ materially from the forward-looking statements we make in this communication are set forth in other reports or documents that we file from time to time with the SEC and the CSA, and include, but are not limited to:

  • the ultimate outcome of the offer and the second-step merger, including the ultimate removal or the failure to render inapplicable the obstacles to consummation of the offer and the second-step merger described in the offer to exchan
    '/>"/>

  • SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
    2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
    3. Valeant Pharmaceuticals To Host Investor Day
    4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
    5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
    6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
    7. Valeant Pharmaceuticals Announces Management Change
    8. Valeant Pharmaceuticals To Syndicate Incremental Loans
    9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
    10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
    11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), and ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2013 through 2020. Also, a ...
    (Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Parasiticides, Vaccines, Anti-Infectives, Medicinal Feed Additives, and Others. The report ... Animals. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
    (Date:9/16/2014)... , Sept. 16, 2014  ROX Medical ... an international multi-center, prospective, randomized, controlled, blinded endpoint ... of arterial hypertension. The CONTROL-HTN trial, NCT01642498, evaluated the ... a fixed connection between a central artery and ... treatment of hypertension. The primary outcomes are reduction ...
    Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Global Animal Medication Industry 2Global Animal Medication Industry 3Global Animal Medication Industry 4Global Animal Medication Industry 5Global Animal Medication Industry 6Global Animal Medication Industry 7Global Animal Medication Industry 8Global Animal Medication Industry 9Global Animal Medication Industry 10Global Animal Medication Industry 11
    (Date:9/16/2014)... 16, 2014 (HealthDay News) -- Although magnesium sulfate is ... preterm delivery, new research suggests it won,t provide any ... effects of magnesium sulfate given to pregnant women, researchers ... behavioral, growth or functional outcomes among those children when ... old. The new findings don,t negate the fact ...
    (Date:9/16/2014)... as part of breast conservation is the current ... (HR+) invasive breast cancer. A new study by ... that combination may not be necessary for all ... results, which Fox Chase researchers presented at the ... on Sunday, September 14, suggest that low-risk patients ...
    (Date:9/16/2014)... DC (PRWEB) September 16, 2014 Programs ... potentially yield hundreds of billions of dollars in savings ... report by the Commonwealth Fund. To help spur these ... seeking up to 10 collaborative groups from across the ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed to ...
    (Date:9/16/2014)... Silver Spring, Md. (PRWEB) September 16, 2014 ... University of Colorado Anschutz Medical Campus and Children’s ... 2014. PHA is the country’s leading pulmonary hypertension association ... hypertension (PH) – a disease of the lungs that affects ... heart failure. Without treatment, mean survivability is only 2.8 years. ...
    (Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... objective scientific way to diagnose major depression in adults, a ... nine genetic indicators (known as "RNA markers") in the blood. ... cognitive behavioral therapy, one of the most common and effective ... Northwestern University researchers report. Depression affects nearly 7 percent ...
    Breaking Medicine News(10 mins):Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
    ... , ARLINGTON, Va., Sept. 3 ... Services Office of Inspector General (OIG) ignored the substantial costs ... to seniors and people with disabilities who require mobility assistance. ... Supplier Acquisition Costs and Services" and dated August 2009. , ...
    ... , AARP Brings the Health Reform Facts ... Minn., Sept. 3 Grab your corn kernels and get ready to cast ... you to take part in the national health reform debate right here at ... lower healthcare costs, make health care more accessible, improve Medicare or lower prescription ...
    ... rate seems no higher than with seasonal flu , ... have died of complications from the H1N1 swine flu ... least 36 children younger than 18, a new government ... who died had at least one chronic high-risk "neurodevelopmental ...
    ... costs, study says , THURSDAY, Sept. 3 ... system are more likely to postpone treatment, potentially hurting ... a new study suggests. , Researchers surveyed 401 Baltimore ... attitudes toward the health care system, including doctors, hospitals ...
    ... 3 Reportlinker.com announces that a new market research report is ... Liver Disease Treatments: The Global Market , ... , , This Report: , ... liver disease treatments, with market forecasts through 2014 , , ...
    ... As millions of teens head back to school, many will be ... Teens are at a greater risk of than any other age group ... Many of those crashes could be avoided with proper education, says The ... education programs. , , NRSF spokesperson David Reich said ...
    Cached Medicine News:Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:Visit AARP's 'Kernels for Healthcare Reform' and Cast Your Vote 2Health News:Swine Flu Poses Risk to Kids With Neurological Conditions 2Health News:Swine Flu Poses Risk to Kids With Neurological Conditions 3Health News:Swine Flu Poses Risk to Kids With Neurological Conditions 4Health News:Mistrust May Cause People to Put Off Treatment 2Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 2Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 3Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 4Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 5Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 6Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 7Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 8Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 9Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 10Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 11Health News:Reportlinker Adds Liver Disease Treatments: The Global Market Report 12Health News:Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation 2
    ... Reticulocyte Stain is an aqueous ... use in manual methods of ... has a one year shelf ... and can be used in ...
    ... Liquichek ToRCH Plus IgM Controls ... problems in your ToRCH IgM ... your test results. Liquichek ToRCH ... perfect complement to Liquichek ToRCH ...
    ... Plus Control is a bilevel ... the performance of the most ... assays. A weak positive and ... to monitor the performance of ...
    Liquichek Unassayed Chemistry Control (Human) is a comprehensive, stable, liquid product designed to monitor general and special chemistry tests....
    Medicine Products: